CERo Therapeutics Holdings, Inc. (CERO)

1.1900 +0.0400 (+3.48%) At close: 04:00PM EDT

CERo Therapeutics Holdings, Inc.

201 Haskins Way
Suite 230
South San Francisco, CA 94080
United States
215-731-9450
https://www.cero.bio

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Daniel Mark Corey M.D.	Founder, CTO & Director	376.04k	N/A	1979
Mr. Brian G. Atwood	President, CEO & Chairman	N/A	N/A	1953
Mr. Charles Ross Carter	CFO, Treasurer & Corporate Secretary	N/A	N/A	1968
Dr. Robert Sikorski M.D., Ph.D.	Consultant	N/A	N/A	1963

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

Corporate governance

CERo Therapeutics Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.